Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 12 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a partnership with Synthon for the development and commercialization of a novel oncology product in the US market. Under this agreement, Synthon will handle the product's development and manufacturing, while Zydus will manage the NDA submission and commercialization. The product aims to reduce pill burden and enhance patient compliance, with a filing expected in the future.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 12, 2025, titled "Zydus and Synthon sign an exclusive development, licensing, supply and commercialization agreement for a novel 505(B)(2) oncology product for the US market".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases